Future analyses will be necessary to evaluate whether this increase of tumor stem cells may cause a greater resistance to therapy of the Btg1-null MBs, especially in consideration of the data by Ward et al. (67), indicating a stronger tumor-initiating ability of CD15+ tumor cells orthotopically transplanted from Shh-type MBs. This evidence concerns the gene BTG1 and neoplasm.